We read with interest the paper of Garin et al (1). This paper
attempts to answer some of the more important questions that remain about
the medium-term management of children admitted following acute
pyelonephritis. Whilst we agree with some conclusions of the paper we are
a little concerned by the authors suggestion that there is no role for
antibiotic prophylaxis in preventing the recurrence of infection in
children. The study as described lacks the power to answer this specific
question. A recent extension to the CONSORT (Consolidated Standards of
Reporting Trials) Statement (2) correctly identifies out the differences
in statistical approaches required to demonstrate equivalence or
noninferiority in randomised trials. Thus a failure to demonstrate
differences between treatment (or non-treatment) arms in this study cannot
be equated as a lack of real difference between the groups. This is
particularly relevant given the relatively low recurrence rate of urinary
tract infections in children on or off prophylaxis.
Furthermore, if we compare the data from children who did or did not
receive antibiotic prophylaxis during the study without vesicoureteric
reflux (VUR) we see that almost one in four (23.3%, n=14) of children who
received no prophylaxis had a subsequent documented urinary tract
infection during the follow up period compared with 8.9% (n=4) in
treatment group. This shows a trend towards a significant benefit for
antibiotic prophylaxis (p=0.052, chi-sqaured test). These observations
would suggest to us that in a child without VUR antibiotic prophylaxis is
likely to be beneficial in reducing the likelihood of subsequent urinary
infection.
For children with VUR the situation is somewhat less clear. Clearly
the apparent excess of children with recurrent pyelonephritis in the
prophylaxis group (12.9% vs 1.7%) is of potential concern. However, the
numbers of children in this study remain small and a much larger study
would be required to successfully answer whether children with VUR do not
derive benefit from antibiotic prophylaxis.
1. Garin EH, Olavarria F, Nieto VG, Valenciano B, Campos A, Young L.
Clinical significance of primary vesiocureteral reflux and unrinary
antibiotic prophylaxis after acute pyelonephritis: a mulitcenter,
randomised, controlled study. Pediatrics 2006;117:626-632.
2. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW, for the
CONSORT group. Reporting of noninferiority and equivalence randomised
trials. JAMA 2006;295:1152-1160.
Conflict of Interest:
None declared